Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Enrollment under way in phase I study of TD-2749 for GI motility dysfunction

Jan. 5, 2005

Pfizer claims compounds with dual 5-HT4 agonist/5-HT3 antagonist activity for GI disorders

Jan. 5, 2005

Zadaxin triple combination therapy tested in new European phase III trial

Dec. 29, 2004

Novel agents for treatment of hepatitis C infection described in a patent

Dec. 28, 2004

Disappointing topline results from phase III study of alvimopan

Dec. 28, 2004

FDA extends review of cilansetron NDA

Dec. 28, 2004

Pegasys approved in Switzerland for chronic hepatitis B

Dec. 27, 2004

Novel lipoxin analogue from Berlex promising for the treatment of IBD

Dec. 22, 2004

Positive E.U. opinion for Pegasys combination therapy in HIV-HCV patients

Dec. 22, 2004

Three patents covering 5-HT4 receptor modulators filed by Dainippon

Dec. 22, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...